Non-selective Day-1 Haemoglobin Monitoring Following Elective Primary Knee Arthroplasty: Clinical Value or Outdated Practice?

择期初次膝关节置换术后第1天非选择性血红蛋白监测:临床价值还是过时的做法?

阅读:2

Abstract

Background Knee arthroplasty is one of the most commonly performed elective surgeries in the UK. Routine Day-1 postoperative haemoglobin (Hb) monitoring is standard practice, but its value is increasingly questioned. Improvements in perioperative care, surgical technique, and the use of adjuncts have significantly reduced blood loss and transfusion rates. Objectives The main objective of this study is to evaluate the need for universal, routine Day-1 Hb monitoring following elective primary knee arthroplasty by assessing the mean Hb drop, the rate of severe anaemia, and the rate of red blood cell (RBC) transfusions. Methods We conducted a retrospective audit of 452 consecutive total and unicondylar primary knee arthroplasties performed by a single surgeon between March 2013 and February 2020. Standardised surgical techniques were employed, including an anteromedial approach, universal tranexamic acid (TXA) and adrenaline administration, avoidance of surgical drains, controlled blood pressure management, and electrocautery haemostasis. A restrictive transfusion protocol was followed (transfusion for symptomatic anaemia or Hb <70 g/L). The primary outcomes were the mean Hb drop, the incidence of severe anaemia, and RBC transfusion rates. Results Mean preoperative Hb was 137.2 ± 14.2 g/L, decreasing to 113.8 ± 14.1 g/L on Day 1 (mean drop: 23.3 ± 9.0 g/L). Only six patients (1.3%) had Day-1 Hb levels below 80 g/L, and 12 patients (2.4%) required postoperative transfusion. No patients were required to return to theatre for haemorrhage control, and no transfusion-related complications occurred. Conclusions With modern blood conservation techniques, universal Day-1 Hb monitoring offers minimal clinical value in elective primary knee arthroplasty. We recommend selective Hb testing for patients with low preoperative Hb levels, relevant comorbidities, or clinical symptoms of anaemia, rather than routine testing for all patients. This approach maintains patient safety while reducing unnecessary interventions, healthcare costs, and environmental impact.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。